Samuel Evetts is the Health Protection Research Unit (HPRU) in Respiratory Infections Manager. The HPRU is a centre-of-excellence; designing, conducting, and sharing internationally-leading, multidisciplinary health protection research with partner, the UK Health Security Agency (UKHSA), with the objective of supporting public health services. The HPRUs strategic coordination remains responsive in its research capacity to address emergent threats and ensure that the partners’ proven track record in translational medicine remains harnessed directly to address public health priorities and health inequalities; best exemplified by the unit’s COVID-19 transmission studies, directly informing government healthcare policy.
Samuel leads in the day-to-day initiation, management and execution of HPRU-related functions, including recruitment, research study logistics, funding applications, financial management of multiple research grants, staff management, administration, National Institute for Health Research (NIHR) annual reporting and contributing to HPRU strategic planning and execution in response to emerging UK healthcare threats.
Samuel is also the HPRU in Respiratory Infections Patient and Public Involvement and Engagement (PPIE) lead. The unit’s PPIE strategy is informed by the belief that engaging with underprivileged, underserved communities and involving them in prioritising research questions and planning health services is a powerful means to reverse health inequalities. The HPRU actively listens to ‘seldom heard’, disadvantaged, communities to feedback into UKHSA policy development and NHS health service planning. This is carried out with HPRU PPIE partners; the Bromley-by-Bow centre, Doctors of the World UK, the Science Museum Group and an established patient and public network.
Samuel holds the position of Director and Trustee for the Mental Health Northampton Collaboration (MHNC); a collective of established voluntary sector providers of mental health services in Northamptonshire. Here he ensures the MHNC pursues its objectives defined in governing documentation and future direction and complies with charity law, company law and any other relevant legislation or regulations. He is also a member of finance sub-committee; ensuring the financial stability of the MHNC.
Prior to joining Imperial College London in August 2020, Samuel held the position of Laboratory and Biobank Manager with the Oxford Parkinson’s Disease Centre (OPDC), University of Oxford. Funded by the UK Monument Trust Discovery Award, here he managed the OPDC laboratory, sample curation, study operations and biobank service. This long-term observational study of Parkinson’s and prodromal Parkinson’s is a world-leading Parkinson’s biomarker biobank and cohort, providing unparalleled opportunity to investigate how movement and cognition change with normal ageing, through the transition to prodromal Parkinson’s, and subsequent conversion to established Parkinson’s.
Education & Professional Membership
Samuel was awarded BSc (Hons) in Biological Sciences, 2008, and MSc in Biomedicine, 2009, from Lancaster University and is a member of the Institute of Science and Technology and Fellow of the Royal Society of Public Health.
et al., 2022, Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study, The Lancet Respiratory Medicine, Vol:10, ISSN:2213-2600, Pages:1061-1073
et al., 2022, Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study., The Lancet. Infectious Diseases, Vol:22, ISSN:1473-3099, Pages:183-195
et al., 2018, Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells, Movement Disorders, Vol:33, ISSN:0885-3185, Pages:1580-1590
et al., 2017, Whole-exome sequencing of 228 patients with sporadic Parkinson's disease, Scientific Reports, Vol:7, ISSN:2045-2322